BioNTech SE

BNTX

US09075V1026

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
90.61 ^USD	-2.55%		-1.16%	-14.15%

May. 17	Sector Update: Health Care Stocks Mixed Late Afternoon	MT
May. 17	Sector Update: Health Care Stocks Softer Friday Afternoon	MT

BIONTECH : Jefferies gives a Neutral rating

May 06, 2024 at 12:46 pm EDT

Jefferies confirms his opinion on the stock and remains Neutral. The target price remains unchanged at USD 100.

Latest news about BioNTech SE

Sector Update: Health Care Stocks Mixed Late Afternoon	May. 17	MT
Sector Update: Health Care Stocks Softer Friday Afternoon	May. 17	MT
Sector Update: Health Care	May. 17	MT
Moderna Wins European Patent Ruling in Covid-19 Vaccine Dispute With Pfizer, BioNTech	May. 17	MT
Moderna Wins European Patent Ruling in Covid-19 Vaccine Dispute With Pfizer, BioNTech	May. 17	MT
Arbutus Biopharma Urged to Stop Share Issuances, Explore Alternatives for Hepatitis B Program	May. 17	MT
Moderna wins case in patent dispute with Pfizer, BioNTech over COVID shot, FT reports	May. 17	RE
Arbutus Biopharma Urged to Stop Share Issuances, Explore Alternatives for Hepatitis B Program	May. 17	MT
Autolus Therapeutics' Q1 Loss Widens, Licensing Revenue Rises	May. 17	MT
Evercore ISI Starts BioNTech With In Line Rating, $100 Price Target	May. 14	MT
BIONTECH : UBS remains Neutral	May. 10	ZD
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	May. 09	MT
HC Wainwright Raises BioNTech SE Price Target to $113 From $107, Maintains Buy Rating	May. 08	MT
BIONTECH : Deutsche Bank reaffirms its Neutral rating	May. 08	ZD
TD Cowen Adjusts BioNTech Price Target to $98 From $95, Maintains Hold Rating	May. 07	MT
BMO Capital Adjusts BioNTech Price Target to $122 From $123, Maintains Outperform Rating	May. 07	MT
Bank Stocks Lead European Equities Traded in the US as American Depositary Receipts Higher Tuesday	May. 07	MT
BIONTECH : Goldman Sachs reiterates its Neutral rating	May. 07	ZD
Sector Update: Health Care Stocks Higher in Late Afternoon Trading	May. 06	MT
Sector Update: Health Care Stocks Advance in Monday Afternoon Trading	May. 06	MT
Sector Update: Health Care	May. 06	MT
BIONTECH : Jefferies gives a Neutral rating	May. 06	ZD
Top Midday Stories: Tyson Shares Tumble on Earnings Miss; Robinhood Receives Wells Notice From SEC Staff; Spirit Airlines to Furlough up to 260 Pilots; Shell in Talks to Sell Malaysian Gas Station Business to Saudi Aramco	May. 06	MT
BioNTech Swings to First-Quarter Loss as Lower COVID-19 Commercial Sales Dents Topline	May. 06	MT
Dpa-AFX Overview: COMPANIES from 06.05.2024 - 15:15	May. 06	DP

BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.

Sector

Biotechnology & Medical Research

Calendar

2024-08-04 - Q2 2024 Earnings Call

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

BIONTECH : A miss is a miss

March 21, 2024 at 09:27 am EDT

More Strategies

Ratings for BioNTech SE

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

83.34 EUR

Average target price

105.4 EUR

Spread / Average Target

+26.45%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
BIONTECH SE	-14.15%	21.87B
VERTEX PHARMACEUTICALS INCORPORATED	+9.42%	115B
REGENERON PHARMACEUTICALS, INC.	+11.84%	106B
ARGENX SE	-1.05%	21.96B
GENMAB A/S	-5.29%	19.21B
BEIGENE, LTD.	-4.16%	18.08B
WUXI APPTEC CO., LTD.	-38.29%	17.71B
NEUROCRINE BIOSCIENCES, INC.	+7.99%	14.32B
SAREPTA THERAPEUTICS, INC.	+36.24%	12.42B
LEGEND BIOTECH CORPORATION	-24.95%	8.23B

Bio Therapeutic Drugs

BioNTech SE

Equities

BNTX

US09075V1026

Biotechnology & Medical Research

BIONTECH : Jefferies gives a Neutral rating

Latest news about BioNTech SE

Chart BioNTech SE

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for BioNTech SE

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs